An Immunoregulatory Role for Complement Receptors in Murine Models of Breast Cancer.
complement C3a
complement C5a
complement receptors
immunoregulation
mammary carcinoma
tumor infiltrating leukocytes
Journal
Antibodies (Basel, Switzerland)
ISSN: 2073-4468
Titre abrégé: Antibodies (Basel)
Pays: Switzerland
ID NLM: 101587489
Informations de publication
Date de publication:
08 Jan 2021
08 Jan 2021
Historique:
received:
28
09
2020
revised:
20
11
2020
accepted:
07
12
2020
entrez:
12
1
2021
pubmed:
13
1
2021
medline:
13
1
2021
Statut:
epublish
Résumé
The complement system has demonstrated roles in regulating tumor growth, although these may differ between tumor types. The current study used two murine breast cancer models (EMT6 and 4T1) to investigate whether pharmacological targeting of receptors for complement proteins C3a (C3aR) and C5a (C5aR1) is protective in murine breast cancer models. In contrast to prior studies in other tumor models, treatment with the selective C5aR1 antagonist PMX53 had no effect on tumor growth. However, treatment of mice with a dual C3aR/C5aR1 agonist (YSFKPMPLaR) significantly slowed mammary tumor development and progression. Examination of receptor expression by quantitative polymerase chain reaction (qPCR) analysis showed very low levels of mRNA expression for either
Identifiants
pubmed: 33430104
pii: antib10010002
doi: 10.3390/antib10010002
pmc: PMC7838807
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Health and Medical Research Council
ID : APP1103951
Organisme : Cancer Council Queensland
ID : N/A
Organisme : The University of Queensland Collaboration and Industry Fund
ID : N/A
Références
PLoS One. 2018 Nov 2;13(11):e0206223
pubmed: 30388137
Nat Rev Immunol. 2018 Jan;18(1):5-18
pubmed: 28920587
J Immunol. 2012 Nov 1;189(9):4674-83
pubmed: 23028051
Biochem Pharmacol. 2020 Oct;180:114156
pubmed: 32682759
Trends Immunol. 2004 Mar;25(3):158-64
pubmed: 15036044
Trends Biochem Sci. 2020 Aug;45(8):693-705
pubmed: 32402749
Nat Commun. 2016 Mar 21;7:11037
pubmed: 26996437
Immunity. 2019 Jul 16;51(1):27-41
pubmed: 31315034
J Immunol. 2017 Apr 1;198(7):2989-2999
pubmed: 28228558
Neoplasia. 2012 Nov;14(11):994-1004
pubmed: 23226093
Mol Ther. 2014 Jan;22(1):18-27
pubmed: 24048441
Cancer Discov. 2019 Feb;9(2):176-198
pubmed: 30679171
FASEB J. 2011 Jul;25(7):2447-55
pubmed: 21490292
J Immunol. 2016 Jun 1;196(11):4783-92
pubmed: 27183625
Int Immunopharmacol. 2008 Jun;8(6):819-27
pubmed: 18442785
Microbiol Immunol. 2002;46(2):131-4
pubmed: 11939578
Inflammation. 2001 Jun;25(3):171-7
pubmed: 11403208
Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9439-44
pubmed: 23696668
Int J Oncol. 2016 May;48(5):2015-24
pubmed: 26935178
Nat Biotechnol. 2008 Dec;26(12):1348-9
pubmed: 19060872
Cancer Chemother Pharmacol. 1989;24(3):148-54
pubmed: 2544306
Breast Cancer Res. 2014 Jun 16;16(3):R63
pubmed: 24935269
Oncoimmunology. 2019 Jun 24;8(9):e1624130
pubmed: 31428522
Mol Immunol. 2009 Sep;46(14):2753-66
pubmed: 19477527
Curr Protoc Immunol. 2001 May;Chapter 20:Unit 20.2
pubmed: 18432775
Vet Pathol. 2012 Jan;49(1):32-43
pubmed: 22135019
Cell Rep. 2014 Mar 27;6(6):1085-1095
pubmed: 24613353
Front Immunol. 2018 Mar 20;9:563
pubmed: 29662489
Oncoimmunology. 2013 Sep 1;2(9):e26137
pubmed: 24228231
Cancer Res. 2014 Jul 1;74(13):3454-65
pubmed: 24786787
Nat Immunol. 2008 Nov;9(11):1225-35
pubmed: 18820683
Exp Cell Biol. 1980;48(2):138-54
pubmed: 7358194
Cancer Immunol Immunother. 2005 Oct;54(10):1026-37
pubmed: 15868168
J Med Chem. 1997 Mar 14;40(6):877-84
pubmed: 9083476
J Immunol. 2019 Jun 15;202(12):3339-3348
pubmed: 31160390
Semin Immunol. 2013 Feb;25(1):54-64
pubmed: 23706991
J Leukoc Biol. 2020 Jul;108(1):339-351
pubmed: 32182389
Pharmacol Rev. 2013 Jan;65(1):500-43
pubmed: 23383423
Am J Pathol. 1992 May;140(5):1039-43
pubmed: 1374587
ACS Omega. 2020 Jan 30;5(5):2345-2354
pubmed: 32064396
BMC Genomics. 2020 Jan 2;21(1):2
pubmed: 31898484
Front Immunol. 2019 May 21;10:1074
pubmed: 31164885
Breast Cancer. 2016 Nov;23(6):876-885
pubmed: 26494574
J Immunol. 2020 Nov 15;205(10):2834-2839
pubmed: 33028618
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
J Immunol. 2012 Sep 15;189(6):2985-94
pubmed: 22914051
J Immunol. 2015 Apr 15;194(8):3542-8
pubmed: 25848071
J Immunol. 2000 Jun 15;164(12):6166-73
pubmed: 10843666
FASEB J. 2019 Oct;33(10):11060-11071
pubmed: 31298935
Front Immunol. 2014 Jun 17;5:276
pubmed: 24987392
J Natl Cancer Inst. 1972 Sep;49(3):735-49
pubmed: 4647494
Appl Immunohistochem Mol Morphol. 2011 Dec;19(6):540-6
pubmed: 21617523
Cell. 2017 Mar 9;168(6):1101-1113.e13
pubmed: 28283064
Br J Pharmacol. 2004 Jun;142(4):756-64
pubmed: 15159277
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Immunol. 2010 Sep;11(9):785-97
pubmed: 20720586
Cancer Immunol Res. 2017 Jan;5(1):29-41
pubmed: 27923825
Am J Respir Crit Care Med. 2018 May 1;197(9):1164-1176
pubmed: 29327939
J Med Chem. 1999 Jun 3;42(11):1965-74
pubmed: 10354404
Cancer Res. 2018 Jan 1;78(1):143-156
pubmed: 29118090